Posted by Michael Wonder on 07 Feb 2022
FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)
3 February 2022 - The U.S. FDA is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib) approved to treat two specific types of lymphomas, which are cancers that affect the body’s immune system.
We determined that initial findings from a clinical trial evaluating Ukoniq to treat a related type of cancer found a possible increased risk of death in patients taking the medicine.
